Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.20 Analyst target: $9.75 Upside: 204.69%
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.